Shikari® Anti-Cetuximab ELISA Kit

$1,330.00

The Shikari® Anti-Cetuximab ELISA Kit has been especially developed for the qualitative analysis of antibodies to cetuximab in serum and plasma samples. The Shikari® Anti-Cetuximab ELISA Kit is for research use only and not to be used for diagnostic procedures.

Anti-Cetuximab antibodies (anti-drug antibodies or ADAs) are immune system proteins developed in response to Cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). These antibodies can arise during treatment and may interfere with Cetuximab’s therapeutic activity by binding to the drug and neutralizing its effects. The formation of anti-Cetuximab antibodies is an indication of an immune response to the biologic and is critical to monitor due to its implications for efficacy, safety, and potential treatment resistance.

In research and clinical settings, the detection of anti-Cetuximab antibodies is essential for therapeutic drug monitoring (TDM). TDM aims to maintain consistent and effective drug levels in the bloodstream while minimizing adverse immune reactions. The presence of anti-Cetuximab antibodies may correlate with altered pharmacokinetics, reduced drug efficacy, or hypersensitivity reactions, making regular monitoring an important part of personalized cancer therapy.

Additionally, the development of anti-Cetuximab antibodies highlights the complexity of biologic therapies. Due to the structural nature of these proteins and the variability in patient immune systems, even minor differences in product formulation, administration routes, or manufacturing can lead to different immune responses. Therefore, assays designed to measure anti-Cetuximab antibodies provide crucial insight into drug tolerance and guide adjustments in therapeutic regimens, especially in patients undergoing prolonged treatment for colorectal or head and neck cancers.

This product is manufactured in Turkey by Matriks Biotek.

Size 1 x 96 Well
Sensitivity 30 ng/mL
Dynamic Range 31.25-500 ng/mL
Incubation Time 2 hours 20 minutes
Sample Type Serum, Plasma
Immunogen
Source Species
Specificity
Expression System
Clone
Group
Alpha Chain
Beta Chain
Peptide
Peptide Source
Format
Buffer
Concentration
Storage 2-8°C
Alternative Names Anti-Cetuximab antibodies, Cetuximab-specific ADAs, Cetuximab-targeting antibodies, Anti-EGFR mAb antibodies, Neutralizing antibodies to Cetuximab, Cetuximab-induced antibodies, Cetuximab-binding immunoglobulins, Cetuximab-directed immune response markers.
Instructions For Use https://eaglebio.com/wp-content/uploads/2025/06/CET-QNS-ERB-Shikari-Anti-Cetuximab-ELISA-instructions-for-use.pdf
MSDS https://eaglebio.com/wp-content/uploads/2025/06/CET-QNS-ERB-Shikari-Anti-Cetuximab-ELISA-safety-data-sheet-sds.pdf

Product Citations